18 F-FDG PET/CT Demonstrates Significant Response in Anaplastic Thyroid Carcinoma Treated With Combined Immunotherapy and Targeted Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41739501.
- Also identified by DOI 10.1097/RLU.0000000000006207.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy with a dismal prognosis and limited responsiveness to conventional therapies. Recent advances in targeted therapy and immunotherapy have shown promise in improving outcomes. 18 F-FDG PET/CT serves as a valuable tool for evaluating disease extent and monitoring therapeutic response in ATC. We present the case of a 51-year-old woman diagnosed with biopsy-proven anaplastic thyroid carcinoma, presenting with extensive locoregional disease and pulmonary metastases on Pembrolizumab and Lenvatinib. 18 F-FDG PET/CT was done for response assessment which showed near complete metabolic response.
Medical subject headings
- Thyroid Carcinoma, Anaplastic
- Fluorodeoxyglucose F18
- Positron Emission Tomography Computed Tomography
- Immunotherapy
- Molecular Targeted Therapy
- Thyroid Neoplasms